



BLA 125557/S-023
BLA 125557/S-026

**SUPPLEMENT APPROVAL
FULFILLMENT OF POSTMARKETING REQUIREMENT
RELEASE FROM POSTMARKETING REQUIREMENT**

Amgen Inc.
Attention: Rajas Chodankar, PhD
Senior Manager, Regulatory Affairs
One Amgen Center Drive
Thousand Oaks, CA 91320-1799

Dear Dr. Chodankar:

Please refer to your supplemental biologics license applications (sBLAs), S-023 dated December 21, 2022, received December 21, 2022, and S-026 dated December 20, 2022, received December 20, 2022, and your amendments, submitted under section 351(a) of the Public Health Service Act for BLINCYTO (blinatumomab) for injection.

Prior Approval supplemental biologics license application S-023 provides data to address PMR 3366-2, for major revisions to Sections 1.1 and 8.4 regarding treatment of acute lymphoblastic leukemia in first or second complete remission with minimal residual disease, and for revisions to Sections 2.5, 5.12 and 5.13 with safety information. Prior Approval supplemental biologics license application S-026 provides for revisions to the Pediatric Use section of the USPI to describe the experience with blinatumomab in the pediatric population based on data from Study AALL1331.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling with minor editorial revisions listed below and reflected in the enclosed labeling.

- Deletion of trailing zeros in table 6 in section 2.6

WAIVER OF HIGHLIGHTS ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,¹ that is identical to the enclosed labeling (text for the Prescribing Information and Medication Guide) and include the labeling changes proposed in any pending “Changes Being Effectuated” (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effectuated” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

SUBPART E FULFILLED

We approved this BLA under the regulations at 21 CFR 601 Subpart E for Accelerated Approval of Biological Products for Serious or Life-Threatening Illnesses. Approval of this supplement fulfills your commitments made under 21 CFR 601.41.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

FULFILLMENT OF POSTMARKETING REQUIREMENT

We have received your submission dated December 21, 2022, reporting on the following postmarketing requirement listed in the March 29, 2018, approval letter for sBLA 125557/S-013.

- 3366-2 Complete a randomized trial and submit the final study report and data sets to verify and describe the clinical benefit of blinatumomab in pediatric patients in morphologic complete remission with detectable minimal residual disease, including efficacy and safety from protocol AALL1331: Risk-stratified Phase III testing of blinatumomab in first relapse of childhood B-lymphoblastic leukemia (B-ALL). Enrollment of approximately 598 patients is expected. The primary endpoint is disease-free survival.

We have reviewed your submission and conclude that the above requirement was fulfilled.

RELEASE FROM POSTMARKETING REQUIREMENT

We have received your submission dated December 21, 2022, related to the following postmarketing requirement listed in our March 29, 2018, approval letter:

- 3366-1 Complete a randomized trial and submit the final study report and data sets to verify and describe the clinical benefit of blinatumomab in adults with acute lymphoblastic leukemia in morphologic complete remission with detectable minimal residual disease, including efficacy and safety from protocol E1910: Combination chemotherapy with or without blinatumomab in treating patients with newly-diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia. Randomization of approximately 280 newly diagnosed patients is expected, and the primary endpoint is overall survival.

Final Protocol Submission:	02/2018
Trial Completion for the Primary Endpoint:	07/2023
Final Report Submission:	04/2025

We have reviewed your submission and have determined that you are released from the above requirement as it is no longer needed because the requirement was met with fulfillment of PMR 3366-2.

This completes all of your postmarketing requirements and postmarketing commitments acknowledged in our March 29, 2018, letter. You are not required to report on the status of closed (released or fulfilled) PMRs/PMC in your annual report required under 21 CFR 601.70 of the FD&CA.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

As required under 21 CFR 601.12(f)(4), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

All promotional materials for your drug product that include representations about your drug product must be promptly revised to make it consistent with the labeling changes approved in this supplement, including any new safety-related information [21 CFR 601.12(a)(4)]. The revisions to your promotional materials should include prominent disclosure of the important new safety-related information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 601.12(a)(4).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Kris Kolibab, Senior Regulatory Project Manager, at (240) 402-0277.

Sincerely,

{See appended electronic signature page}

R. Angelo de Claro, MD
Division Director
Division of Hematologic Malignancies I
Office of Oncologic Diseases
Center for Drug Evaluation and Research

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

BLA 125557/S-023

BLA 125557/S-026

Page 5

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Medication Guide

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ROMEO A DE CLARO
06/20/2023 10:00:37 AM